Announcements Trials
Browse Landscape

Status

Completed 89Recruiting 20Terminated 18Active not recruiting 13Unknown 12Withdrawn 7Not yet recruiting 4No longer available 3Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 3

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1

Conditions

Solid Tumors 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Axitinib × Clear all
NCT05941637 2024-12-31

An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

Lynkcell Europe

No longer available
Genitourinary

Kidney Neoplasms

NCT02354612 2021-02-15

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Tracon Pharmaceuticals Inc.

No longer available
Other solid neoplasm

Solid Tumors

NCT01473043 2014-05-30

Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

Pfizer

No longer available
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡